Nurix Therapeutics (NASDAQ:NRIX) Director Sells $528,442.20 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Director Julia Gregory sold 22,583 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total transaction of $528,442.20. Following the completion of the transaction, the director directly owned 10,750 shares in the company, valued at $251,550. The trade was a 67.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $24.42 on Friday. The firm has a 50-day moving average of $25.11 and a 200-day moving average of $21.16. The stock has a market cap of $2.67 billion, a PE ratio of 10.57 and a beta of 1.82. Nurix Therapeutics, Inc. has a 52-week low of $9.71 and a 52-week high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Monday, October 12th. The company reported $4.73 EPS for the quarter, topping the consensus estimate of ($0.60) by $5.33. The business had revenue of $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. As a group, analysts predict that Nurix Therapeutics, Inc. will post 0.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. HC Wainwright increased their target price on Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Friday. Needham & Company LLC restated a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research note on Tuesday. Stifel Nicolaus set a $41.00 price objective on Nurix Therapeutics in a report on Tuesday. Royal Bank Of Canada decreased their price objective on Nurix Therapeutics from $36.00 to $35.00 and set an “outperform” rating on the stock in a report on Tuesday. Finally, Wall Street Zen raised Nurix Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Nurix Therapeutics during the second quarter worth approximately $212,769,000. General Atlantic L.P. bought a new stake in shares of Nurix Therapeutics in the fourth quarter valued at approximately $92,899,000. Perceptive Advisors LLC boosted its stake in shares of Nurix Therapeutics by 151.1% in the fourth quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock valued at $67,455,000 after buying an additional 2,139,728 shares during the period. Trails Edge Capital Partners LP bought a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $38,166,318. Finally, Bank of America Corp DE acquired a new stake in Nurix Therapeutics during the second quarter worth approximately $20,429,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.